Skip to main content

Loumeau Eric J's Form 4 filing

Anaptysbio, IncANAB · filed Sep 17, 2024

Accession no.
0001415889-24-023551
Filed
Sep 17, 2024
Trade date
Sep 14-17, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $492.5K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Loumeau Eric JCIK 0001239648Officer (CHIEF LEGAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 14, 2024Common StockMOption exerciseAcquired+6,000$0.00F1$010,740Direct
Sep 16, 2024Common StockSSaleDisposed−2,220$38.93−$86,424.68,520Direct
Sep 16, 2024Common StockMOption exerciseAcquired+5,000$14.02+$70,10013,520Direct
Sep 16, 2024Common StockSSaleDisposed−6,500$40.13−$260,8457,020Direct
Sep 17, 2024Common StockSSaleDisposed−3,780$38.41F5−$145,189.83,240Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 14, 2024Common StockMOption exerciseDisposed−6,000$0.00$00Direct
Sep 16, 2024Common StockMOption exerciseDisposed−5,000$0.00$073,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 1 transaction in Table I.

F5

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $38.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)